[go: up one dir, main page]

PL2382990T3 - Sposoby leczenia raka z zastosowaniem immunotoksyny - Google Patents

Sposoby leczenia raka z zastosowaniem immunotoksyny

Info

Publication number
PL2382990T3
PL2382990T3 PL10011667T PL10011667T PL2382990T3 PL 2382990 T3 PL2382990 T3 PL 2382990T3 PL 10011667 T PL10011667 T PL 10011667T PL 10011667 T PL10011667 T PL 10011667T PL 2382990 T3 PL2382990 T3 PL 2382990T3
Authority
PL
Poland
Prior art keywords
immunotoxin
methods
treating cancer
cancer
treating
Prior art date
Application number
PL10011667T
Other languages
English (en)
Inventor
Uwe Zangenmeister-Wittke
Paolo Claudio Di
Dominique Christine Tschudi
Nicholas Ronald Glover
Dimitri Peter Fitsialos
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of PL2382990T3 publication Critical patent/PL2382990T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL10011667T 2003-04-30 2004-04-30 Sposoby leczenia raka z zastosowaniem immunotoksyny PL2382990T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46660803P 2003-04-30 2003-04-30
EP04730425A EP1635868A1 (en) 2003-04-30 2004-04-30 Methods for treating cancer using an immunotoxin
EP10011667.2A EP2382990B1 (en) 2003-04-30 2004-04-30 Methods for treating cancer using an immunotoxin

Publications (1)

Publication Number Publication Date
PL2382990T3 true PL2382990T3 (pl) 2015-04-30

Family

ID=33418401

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10011667T PL2382990T3 (pl) 2003-04-30 2004-04-30 Sposoby leczenia raka z zastosowaniem immunotoksyny
PL14172801T PL2829283T3 (pl) 2003-04-30 2004-04-30 Sposoby leczenia nowotworu z zastosowaniem immunotoksyny

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14172801T PL2829283T3 (pl) 2003-04-30 2004-04-30 Sposoby leczenia nowotworu z zastosowaniem immunotoksyny

Country Status (14)

Country Link
US (6) US20070196366A1 (pl)
EP (3) EP2829283B1 (pl)
JP (1) JP4988333B2 (pl)
CN (1) CN100417414C (pl)
AU (1) AU2004234191A1 (pl)
CA (2) CA2524124C (pl)
DK (2) DK2829283T3 (pl)
ES (2) ES2526219T3 (pl)
HK (1) HK1206617A1 (pl)
HU (1) HUE033533T2 (pl)
IL (2) IL171643A (pl)
PL (2) PL2382990T3 (pl)
PT (2) PT2382990E (pl)
WO (1) WO2004096271A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1918303A3 (en) 1999-04-09 2008-05-14 Universität Zürich method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
JP4986370B2 (ja) 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｒｇｍおよびそのモジュレーターの用途
AU2004234191A1 (en) 2003-04-30 2004-11-11 University Of Zurich Methods for treating cancer using an immunotoxin
US20060127399A1 (en) * 2004-09-13 2006-06-15 Defu Zeng Compositions and methods for inducing chimerism in a subject
WO2006074451A2 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
CA2597638A1 (en) * 2005-02-16 2006-08-24 University Of Zuerich Methods for treating cancer using an immunotoxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by mmp-2 or mmp-9
CA2652434A1 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized proteins that target ep-cam
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
CA2633138A1 (en) * 2005-12-23 2007-06-28 Viventia Biotech Inc. Methods for generating and screening fusion protein libraries and uses thereof
CA2684330A1 (en) 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
WO2009039630A1 (en) * 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
US8110193B2 (en) * 2007-12-21 2012-02-07 City Of Hope Methods for conditioning a subject for hematopoietic cell transplantation
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
US20100055107A1 (en) * 2008-07-31 2010-03-04 Defu Zeng Methods for preventing hematological malignancies and graft versus host disease by anti-cd3 preconditioning
AU2009311233B2 (en) * 2008-11-06 2015-01-15 University Of Guelph Methods of improving the therapeutic efficacy and utility of antibody fragments
CA2867252C (en) * 2008-12-05 2015-09-01 Abraxis Bioscience, Llc Albumin binding peptide-mediated disease targeting
US20120121591A1 (en) 2009-03-20 2012-05-17 Amgen Inc. SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
WO2011031441A1 (en) * 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
CA2773907A1 (en) 2009-09-21 2011-03-24 Mount Sinai Hospital Methods and compositions for the diagnosis and treatment of thyroid cancer
CN102639555B (zh) * 2009-09-24 2015-11-25 加利福尼亚大学董事会 膀胱癌特异性配体肽
WO2011047135A2 (en) * 2009-10-14 2011-04-21 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treating bladder cancer
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
US20110275530A1 (en) 2010-05-04 2011-11-10 Paul Walfish Methods and compositions for the diagnosis and treatment of epithelial cancers
CA2814780C (en) 2010-09-22 2017-05-16 Amgen Inc. Carrier immunoglobulins and uses thereof
IL297229A (en) 2012-01-27 2022-12-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
SG11201508419PA (en) * 2013-04-12 2015-11-27 Viventia Bio Inc Compositions and methods for detection and treatment of hepatocellular carcinoma
EP3052525B1 (en) 2013-10-02 2019-07-24 Viventia Bio Inc. Anti-epcam antibodies and methods of use
US10576163B2 (en) 2015-03-12 2020-03-03 Viventia Bio Inc. Methods of treatment for EpCAM positive bladder cancer
US10583198B2 (en) 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
CN110430885A (zh) * 2017-03-22 2019-11-08 学校法人兵库医科大学 用于对标准化疗不反应或不耐受且无法根治性切除的进行性或复发性癌患者的治疗的药物
WO2018220467A1 (en) * 2017-05-30 2018-12-06 Foroogh Nejatollahi Anti-muc18 human immunotoxin and applications thereof
AU2018301651B2 (en) 2017-07-10 2023-05-18 Sri International A peptide saporin conjugate for the treatment of cancer
CN108122613B (zh) * 2018-01-15 2022-04-01 北京颐圣智能科技有限公司 基于健康预测模型的健康预测方法和装置
CN110194803B (zh) * 2019-06-26 2021-01-05 上海科棋药业科技有限公司 一种靶向EpCAM的嵌合抗原受体及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4677070A (en) 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US5082927A (en) 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US4933288A (en) 1986-11-21 1990-06-12 Cetus Corporation Use of a modified soluble Pseudomonas exotoxin A in immunoconjugates
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5621078A (en) 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
WO1991009949A1 (en) 1990-01-02 1991-07-11 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Target-specific, cytotoxic, recombinant pseudomonas exotoxin
US5458878A (en) 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
DE69131449T2 (de) 1990-05-11 1999-11-25 The United States Of America, Represented By The Secretary Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
CA2136724A1 (en) 1992-06-18 1993-12-23 Ira H. Pastan Recombinant pseudomonas exotoxin with increased activity
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
CA2234666A1 (en) 1995-10-13 1997-04-17 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment
IL116559A (en) 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
JP2000511050A (ja) 1996-05-31 2000-08-29 メディジーン・アクチェンゲゼルシャフト 機能性分子表面の生成、スクリーニング、および展開のための新規の合成タンパク質の構造の鋳型
CA2271291A1 (en) 1996-11-06 1998-05-14 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US6180341B1 (en) 1997-05-01 2001-01-30 Board Of Regents, The Universiry Of Texas System In vitro scanning saturation mutagenesis of proteins
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
WO1998055623A1 (en) 1997-06-06 1998-12-10 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
DK1037927T3 (da) * 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
EP1918303A3 (en) * 1999-04-09 2008-05-14 Universität Zürich method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
GB9911569D0 (en) * 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
AU2002213251B2 (en) 2000-10-16 2007-06-14 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2002090566A2 (en) 2001-05-03 2002-11-14 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
US20030148950A1 (en) 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
IL161418A0 (en) * 2001-10-15 2004-09-27 Immunomedics Inc Direct targeting binding proteins
US20040022726A1 (en) 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
SI21272A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli
CA2424255A1 (en) 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
AU2004234191A1 (en) 2003-04-30 2004-11-11 University Of Zurich Methods for treating cancer using an immunotoxin
PL1737961T3 (pl) 2004-03-19 2013-12-31 Merck Patent Gmbh Zmodyfikowane białka bouganiny, cytotoksyny i sposoby oraz ich zastosowania
AU2005252275B2 (en) 2004-06-10 2011-07-21 Viventia Bio Inc. Tumor specific antibody
US20090171317A1 (en) 2006-03-10 2009-07-02 Ebrahim Versi Self-Catheterization Device To Administes Compounds To The Bladder
EP2079840A4 (en) 2006-10-30 2010-06-30 Viventia Biotech Inc IMMUNOTOXIN FUSIONS COMPRISING PROTEASEPLATABLE LINKER-ASSOCIATED ANTIBODY FRAGMENT AND PLANT TOXIN
CA2684330A1 (en) 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
WO2009039630A1 (en) 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
JP2012523383A (ja) 2009-04-08 2012-10-04 ファウルシュティヒ，ハインツ がんの治療のためのアマトキシンと複合体形成した標的結合部分
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
JP2014523884A (ja) 2011-06-24 2014-09-18 セントローズ， エルエルシー 細胞外標的化薬物複合体
SG11201508419PA (en) 2013-04-12 2015-11-27 Viventia Bio Inc Compositions and methods for detection and treatment of hepatocellular carcinoma
EP3052525B1 (en) 2013-10-02 2019-07-24 Viventia Bio Inc. Anti-epcam antibodies and methods of use
US10583198B2 (en) 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
WO2017040801A2 (en) 2015-09-02 2017-03-09 Viventia Bio Inc. Methods for making and using an immunoconjugate for the treatment of cancer

Also Published As

Publication number Publication date
US20160199507A1 (en) 2016-07-14
DK2382990T3 (en) 2014-12-15
US9259484B2 (en) 2016-02-16
CA2826735C (en) 2019-06-04
ES2526219T3 (es) 2015-01-08
PT2829283T (pt) 2017-09-08
EP2829283B1 (en) 2017-06-07
US10858429B2 (en) 2020-12-08
US8545840B2 (en) 2013-10-01
CA2826735A1 (en) 2004-11-11
EP1635868A1 (en) 2006-03-22
AU2004234191A1 (en) 2004-11-11
IL171643A (en) 2011-08-31
CN100417414C (zh) 2008-09-10
CA2524124A1 (en) 2004-11-11
HUE033533T2 (en) 2017-12-28
US20140178417A1 (en) 2014-06-26
US11713351B2 (en) 2023-08-01
ES2639301T3 (es) 2017-10-26
US20210317203A1 (en) 2021-10-14
US20210040203A1 (en) 2021-02-11
JP4988333B2 (ja) 2012-08-01
EP2382990A1 (en) 2011-11-02
DK2829283T3 (en) 2017-09-18
IL213621A (en) 2013-12-31
CA2524124C (en) 2014-03-25
US11713352B2 (en) 2023-08-01
PL2829283T3 (pl) 2017-12-29
EP2382990B1 (en) 2014-09-17
JP2006526576A (ja) 2006-11-24
PT2382990E (pt) 2014-12-29
IL213621A0 (en) 2011-07-31
US20100249039A1 (en) 2010-09-30
EP2829283A1 (en) 2015-01-28
HK1206617A1 (en) 2016-01-15
CN1816352A (zh) 2006-08-09
US20070196366A1 (en) 2007-08-23
WO2004096271A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
HK1206617A1 (en) Methods for treating cancer using an immunotoxin
EP2671581B8 (en) Compositions and methods for treating cancer
SG133592A1 (en) Methods for treating prostate cancer with herbal compositions
ZA200508427B (en) Methods for treating interleuking-6 related diseases
EP1696877A4 (en) PROCESS FOR PAIN TREATMENT
IL176919A0 (en) Methods and compositions for treating cancer
IL183059A0 (en) Cancer treatment method
EP1909854A4 (en) METHOD FOR TREATING CANCER
EP1468118A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL179323A0 (en) Cancer treatment method
EP1755394A4 (en) METHOD OF TREATING CANCER
PT1830847E (pt) Tratamento para o cancro
IL179359A0 (en) Cancer treatment method
PL379264A1 (pl) Kompozycje i sposoby leczenia raka przy zastosowaniu IGSF9 i LIV-1
EP1401377A4 (en) CANCER TREATMENT METHODS
GB0428187D0 (en) Cancer treatment
IL175689A0 (en) Enoxaparin for the treatment of cancer
GB0413346D0 (en) Treating cancer
EP1802617A4 (en) CANCER TREATMENT METHOD
EP1599214A4 (en) METHODS AND COMPOSITIONS FOR TREATING UTERINE COLON CANCER
GB0223325D0 (en) Treating cancer
GB0404675D0 (en) Cancer treatment
GB2383538B (en) Cancer treatment
GB0327499D0 (en) Cancer treatment
GB0329081D0 (en) Radiotherapy apparatus